SOURCE: Amarin Corp. Plc


March 09, 2016 12:30 ET

Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation

Final Order of Approval Issued Concluding First Amendment Litigation

BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - March 09, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the Honorable Judge Paul A. Engelmayer of the United States District Court for the Southern District of New York has approved the settlement terms proposed by the parties related to the Amarin First Amendment litigation (Amarin Pharma, Inc. et al. v. FDA et al., No. 15-3588 (S.D.N.Y. May 7, 2015)) and disclosed in Amarin's press release dated March 8, 2016. The Court has entered a final order of approval reflecting these terms and concluding the underlying litigation.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to the ongoing REDUCE-IT cardiovascular outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit For more information about Amarin, visit

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website (, our investor relations website (, including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Contact Information